BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive topline results from a Phase 2a trial of GB2064 for the treatment of myelofibrosis (the “MYLOX-1 trial”, NCT04679870 ). The MYLOX-1 trial dosed a total of 18 myelofibrosis patients, of which 11 (61%) patients had... Read More